Posts

Posted on

Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm – IPHI, XLNX, WTRE, CXO

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:


Inphi


Corporation (NASDAQ: IPHI)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Marvell Technology Group Ltd. for $66.00 in cash and 2.323 shares of stock of the combined company for each Inphi share. If you are an Inphi shareholder, click on this link to learn more about your legal rights and options:https://halpersadeh.com/actions/inphi-corporation-iphi-stock-merger-marvell/.


Xilinx, Inc. (NASDAQ: XLNX)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Advanced Micro Devices, Inc. for 1.7234 shares of AMD common stock for each share of Xilinx common stock. If you are a Xilinx shareholder, click on this link to learn more about your legal rights and options:https://halpersadeh.com/actions/xilinx-inc-xlnx-stock-merger-amd/.


Watford Holdings Ltd. (NASDAQ: WTRE)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Arch Capital Group Ltd. for $35.00 per share. If you are a Watford shareholder, click on this link to learn more about your legal rights and options:https://halpersadeh.com/actions/watford-holdings-ltd-wtre-stock-merger-arch-capital/.


Concho Resources Inc. (NYSE: CXO)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ConocoPhillips. Under the terms of the merger, Concho shareholders will receive 1.46 shares of ConocoPhillips common stock for each share of Concho common stock they own. If you are a Concho shareholder, click on this link to learn more about your rights and options:https://halpersadeh.com/actions/concho-resources-inc-stock-merger-conocophillips.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com



Posted on

OneWater Marine Inc. Announces Definitive Agreement to Acquire Tom George Yacht Group

Extends presence in attractive Florida market and marks a return to OneWater’s M&A Strategy

BUFORD, Ga., Nov. 18, 2020 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or “the Company”) announced today that it has entered into a definitive agreement to acquire substantially all of the assets of Tom George Yacht Group (“TGYG”), which will enhance the Company’s presence on the west coast of Florida and expand new and pre-owned boat sales, as well as yacht brokerage and service & parts. The transaction is expected to close before the end of the calendar year.

With an operating history of more than 11 years and two locations to serve customers, TGYG is an authorized dealer for a number of prestigious brands, including Everglades, Cobalt, and EdgeWater, Invincible, Marquis, and Carver, among others. In addition, TGYG offers quality service and parts, as well as finance and insurance, to its loyal and growing customer base. TGYG generated revenues in excess of $30 million over the past twelve months from these offerings.

“We are pleased to welcome Tom George and his team to the OneWater family. TGYG further diversifies our product portfolio and deepens our presence in Florida, particularly in the Clearwater and Dunedin markets. Since 2014, we have successfully acquired 40 retail locations; this transaction marks the first since going public in early fiscal year 2020 and is one of the largest acquisitions in the Company’s history. We have a strong track record delivering operational synergies and fueling margin expansion by working collaboratively with our dealers to identify and implement opportunities expanding our offering and process improvement. We look forward to supporting their continued growth in the future,” said Austin Singleton, Chief Executive Officer of OneWater.

Tom George, owner of TGYG, said, “We are thrilled to be joining the OneWater network of dealerships. TGYG has cultivated a premium product portfolio and has a strong reputation for delivering superior customer service, making it a perfect addition for OneWater. Now having access to OneWater’s digital platform, finance & insurance capabilities, and best practices, I believe we can take the business to new heights, maximizing new and existing revenue streams and overall operating efficiency. I couldn’t be more excited about this partnership and the opportunities that lie ahead for our team.”

About OneWater Marine Inc.

OneWater Marine Inc. is one of the largest and fastest-growing premium recreational boat retailers in the United States. OneWater operates 61 stores throughout 10 different states, eight of which are in the top twenty states for marine retail expenditures. OneWater offers a broad range of products and services and has diversified revenue streams, which include the sale of new and pre-owned boats, parts and accessories, finance and insurance products, maintenance and repair services and ancillary services such as boat storage.

Investor or Media Contact:

Jack Ezzell
Chief Financial Officer
[email protected]

Cautionary Statement Concerning Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including regarding our plans and expectations for TGYG and our digital platform, future strategy, future operations, financial position, prospects, plans and objectives of management, growth rate and its expectations regarding future revenue, operating income or loss or earnings or loss per share. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “will be,” “will likely result,” “should,” “expects,” “plans,” “anticipates,” “could,” “would,” “foresees,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “outlook” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management’s current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct.

Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: risks related to the satisfaction of the conditions to closing the acquisition in the anticipated timeframe or at all, risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period, the risk that the businesses will not be integrated successfully, decline in demand for our products and services, the seasonality and volatility of the boat industry, our acquisition strategies, the inability to comply with the financial and other covenants and metrics in our credit facilities, cash flow and access to capital, effects of the COVID-19 pandemic and related governmental actions or restrictions on the Company’s business, the timing of development expenditures, and other risks. More information on these risks and other potential factors that could affect our financial results is included in our filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the prospectus filed in connection with our Registration Statement on Form S-1 (File No. 333-248774), filed on September 14, 2020. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.



Posted on

Tokenized Investment-Grade Diamonds Can Now Be Enjoyed As Jewelry and Re-Tokenized For Investment Trading

Denver, CO, Nov. 18, 2020 (GLOBE NEWSWIRE) — (via Blockchain Wire) Icecap, the pioneering platform that offers investment-grade diamonds represented by non-fungible blockchain tokens on the Ethereum blockchain, today announced a new option for holders of its diamond-based tokens: the diamond to be enjoyed as jewelry while in an investment portfolio. 

Icecap uses the Ethereum ERC-721 standard to create a blockchain token for each individual diamond it offers. The token can be sold back-and-forth on NFT trading platforms such as Opensea.io in a frictionless environment, while the diamond itself remains in an insured vault facility in New York City. 

Icecap has now expanded this program to allow a token owner to redeem the token, take possession of the underlying diamond, enjoy it as jewelry for months or years, and then re-tokenize it later so it can be placed back into the blockchain-based marketplace for trading purposes.

“Up until now, a token buyer had only two choices,” explained Jacques Voorhees, Icecap CEO.  “They could either keep the diamond in tokenized form while the diamond itself remained in an insured vault, so its token could be traded in a frictionless environment; or they could redeem the token and take delivery of the diamond to enjoy as jewelry. But at that point the token is burned, and the diamond is not able to be traded or liquidated as part of an investment portfolio.”

“But with this new service, the best of both worlds are possible,” Voorhees continued. “Any token owner can now take possession of the diamond immediately and enjoy it as jewelry.  Later, a small re-tokenization fee is charged to place the diamond back in the vault facility, and the diamond is represented again via a token which can be traded in a frictionless environment.” 

Because it’s an investor-oriented marketplace, Icecap diamonds are sold at merely five percent above wholesale cost. By comparison, aggressive e-tailers markup diamonds approximately twenty percent, while brick-and-mortar stores generally markup twenty-five percent and above.

“There is no longer a reason investment-grade diamonds, purchased as part of a hard-asset portfolio, shouldn’t also be used for adornment in the meantime,” said Icecap Chief Operating Officer, Krista Olson Blundell. “Investment-grade merely means the diamonds are verified to extremely exacting standards, beyond what a GIA certificate provides. The grading is actually guaranteed, and the diamonds are immune to the gemological problems that occur with non investment-grade stones. This tight verification is because investment-grade diamonds must be able to be sold as easily as they are purchased, and this exacting grading process ensures that’s possible. However, this just means investment-grade diamonds are that much more beautiful, and that much more worthy to be showcased as jewelry.” 

“A hard asset portfolio partially diversified into diamonds, where those diamonds can be worn in the meantime by a loved one, yields double-value,” continued Voorhees. “You’re investing in both hard assets and in a relationship. In fact, an investment-grade diamond set in an engagement ring guarantees not only a diamond that is forever, but value that is forever as well.”

For more information on Icecap, please visit https://icecap.diamonds/. To visit the OpenSea marketplace directly, go to https://opensea.io/assets/icecap-diamonds.

About Icecap

Icecap, LLC, created in January 2020 and which opened for business in August, is the first company to use the ERC721 Non-Fungible Token (NFT) standard to provide a revolutionary way to buy and sell diamonds. By making the tokens tradeable, while the diamond is kept in a secure vault (redeemable at any time), the normal friction for diamond investors is removed, and the buy/sell spreads are reduced to ten percent or less.  Icecap buys diamonds on the wholesale market, creates tokens which each represent a claim on a given diamond, and sells those tokens on the OpenSea marketplace, at or below normal e-tail price levels for comparable stones. www.icecap.diamonds



[email protected]

Posted on

ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin, a Vital Medication

ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin, a Vital Medication

CHARLOTTE, N.C.–(BUSINESS WIRE)–Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Fresenius Kabi to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.

Heparin is an anticoagulant that prevents the formation of blood clots that can ultimately lead to venous and arterial thromboembolic events if not properly treated. The drug has been on the U.S. Food and Drug Administration (FDA) drug shortage list since 2017. However, shortages have been exacerbated recently, as research shows that between 25 and 40 percent of patients hospitalized with COVID-19 develop blood clots and require medications like heparin upon admission. These same patients remain at risk for clots up to 90 days post-discharge and that may extend the need for anticoagulation therapy.

“Premier data shows that demand for anti-clotting medications can spike by as much as 46 percent during surge periods,” said Premier’s President, Michael J. Alkire. “As COVID-19 cases increase across the country, the partnership between Premier and Fresenius Kabi will help avoid shortages for the benefit of the patients who need this life-saving drug. Longer term, a ready supply of heparin is a pre-condition for resuming routine and elective procedures in the hospital setting.”

Heparin has historically experienced supply volatility due to difficulties associated with obtaining the active pharmaceutical ingredient (API) necessary to make it. API for heparin is derived from porcine intestines. Estimates suggest that approximately 45 percent of all the API used to make heparin is sourced from China. This overreliance has led to shortages when quality problems and other supply chain disruptions occur. To help mitigate this problem and assure adequate supply to meet a potential future surge in demand, Fresenius Kabi sources its raw materials from multiple regions.

Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. It is a leading provider of generic injectables for U.S. hospitals and is known for its award-winning service.

“Sourcing heparin has been an ongoing challenge,” said Dr. Michael Molby, pharmacy supply chain manager for Atrium Health, a Premier member hospital system based in Charlotte, North Carolina. “Having a resilient and reliable supply chain is essential. This is something that’s needed in intensive care units, especially during this time when we’re dealing with higher patient numbers due to COVID-19. It is crucial in providing patient care and our ability to save lives.”

Guided by health systems with more than 1,600 hospitals across the nation, Premier’s ProvideGx program creates long-term committed buying contracts that provide participating manufacturers with the surety needed to increase production or move into new markets. Premier’s programs, including ProvideGx, currently provide members access to more than 150 drugs that are or have been recently designated as shortage drugs, with a pipeline of more than 50 additional drugs. The program has also ensured an adequate safety stock of medicines and has successfully protected supply even as demand surged more than 150 percent during the COVID-19 pandemic.

The financial terms of Premier’s agreement with Fresenius Kabi were not disclosed.

Forward-Looking Statements

Matters discussed in this release that are not statements of historical or current facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Premier’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premier’s control. More information on potential factors that could affect Premier’s financial results is included from time to time in the “Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC and available on Premier’s website at investors.premierinc.com. Forward-looking statements speak only as of the date they are made. Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

About Premier Inc.

Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,100 U.S. hospitals and health systems and approximately 200,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.

Amanda Forster,[email protected]

 

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: General Health Other Health Hospitals Health Pharmaceutical

MEDIA:

Logo
Logo
Posted on

New Jersey Government Awards CompuCom a Class D Electronic Waste Recycling Permit

New Jersey Government Awards CompuCom a Class D Electronic Waste Recycling Permit

New Certification Proves CompuCom’s e-waste Management Competency and Expands its Recycling Capacity

FORT MILL, S.C.–(BUSINESS WIRE)–
CompuCom, a managed services provider and wholly owned subsidiary of The ODP Corporation (NASDAQ:ODP), a leading provider of business services, products and digital workplace technology solutions through an integrated B2B distribution platform, announced today that it has been awarded a Class D Permit (Universal Waste) for its facility in Paulsboro, New Jersey. The permit, established under the New Jersey electronic waste management act, enables CompuCom to operate as an e-waste recycling facility for the safe and environmentally sound management of end-of-life electronic devices and components.

“CompuCom is honored to have accomplished this certification which recognizes our competence in the proper handling and disposal of e-waste in the state of New Jersey,” said Mick Slattery, president for CompuCom. “As the accumulation of e-waste continues to grow, we have partnered with our parent company, The ODP Corporation to establish the GreenerOffice™ program to help our customers assess and minimize their environmental impact on the planet.”

CompuCom views sustainability as another challenge it can help its customers address and sees its role as a specialized recycler as essential for providing the technology needed to extract raw materials and precious metals while also maintaining environmental safety. The company’s IT Asset Disposition Program (ITAD) reduces e-waste associated with outdated technology and includes the careful tracking of devices with a full chain of custody along with the certificate of recycling and data destruction.

About CompuCom

CompuCom is a wholly owned subsidiary of The ODP Corporation (NASDAQ:ODP), a leading provider of business services and supplies, products and digital workplace technology solutions to small, medium and enterprise businesses, through an integrated business-to-business (B2B) distribution platform, which includes world-class supply chain and distribution operations, dedicated sales professionals and technicians, online presence, and approximately 1,200 stores. CompuCom provides end-to-end managed workplace services, infrastructure modernization and digital consulting to enable the digital workplace for enterprise, midsize and small businesses. For more information, visit compucom.com.

Arthur Bailey

CompuCom

[email protected]

Mitch Polikoff

BCW | Burson Cohn & Wolfe

[email protected]

KEYWORDS: United States North America New Jersey South Carolina

INDUSTRY KEYWORDS: Technology Other Technology Data Management Environment

MEDIA:

Logo
Logo
Posted on

MedAvail and MYOS RENS Technology Announce Closing of Business Combination

MedAvail and MYOS RENS Technology Announce Closing of Business Combination

MedAvail, Inc. Set to Trade on NASDAQ Under Ticker Symbol “MDVL”

MISSISSAUGA, Ontario & CEDAR KNOLLS, N.J.–(BUSINESS WIRE)–
MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle. The combined company will focus on the MedAvail business and its shares will trade on the Nasdaq Capital Market under the new trading symbol “MDVL.” The current MYOS RENS muscle health business will be spun off as a private unaffiliated company.

MedAvail will be led by its current experienced executive team with Ed Kilroy as CEO.

“We are excited to partner with our private placement investors as we continue to execute on MedAvail’s growth plan as a public company,” said Mr. Kilroy. “We believe MedAvail is uniquely positioned in the healthcare value chain. Our experience to date has demonstrated that by embedding pharmacy at these points of care we can positively impact medication adherence and deliver superior customer satisfaction. Our presence in each clinic drives our customer acquisition, allowing us to build a substantial pharmacy business in each clinic we deploy. We also provide our customers free home courier delivery. Currently we are deployed in Arizona and California with plans to open new care settings in Michigan, Florida, Illinois and Texas in the future.”

MedAvail currently deploys its proprietary MedCenter solution through two distinct commercialization channels: its SpotRx full-service retail pharmacy platform in the United States, which has over 40 clinics deployed across Arizona and California, and its technologies channel which sells its MedCenter kiosk and licenses its software to large retailers and health systems.

Cowen served as financial and capital markets advisor to MedAvail, and Lake Street Capital Markets acted as a placement agent on the private offering. Wilson Sonsini Goodrich & Rosati, PC served as legal counsel to MedAvail. H.C. Wainwright & Co. served as financial advisor to MYOS RENS, and Hiller, PC and Ellenoff Grossman & Schole LLP served as legal counsel to MYOS RENS.

About MedAvail

MedAvail is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at www.medavail.com.

About MYOS RENS Technology

MYOS RENS Technology Inc., “The Muscle Company®”, is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness and produces muscle health support products featuring Fortetropin under the names of Yolked®, Physician Muscle Health Formula®, MYOS Canine Muscle Formula®, (Regular & Vet Strength) and Qurr®. For more information, please visit www.myosrens.com.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the company’s expected uses of proceeds from the business combination; potential future revenue and expansion plans; and market opportunity. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of MedAvail’s management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of COVID-19; the outcome of judicial proceedings to which MedAvail is, or may become a party; changes in competitive conditions prevailing in the healthcare sector; the availability of capital; and the other risks discussed under the heading “Risk Factors” in a Registration Statement on Form S-4 (“Form S-4”), which was declared effective by the SEC on October 15, 2020, and other documents MedAvail files with the SEC in the future. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and MedAvail specifically disclaims any obligation to update these forward-looking statements.

Investor Relations

Caroline Paul

Gilmartin Group

[email protected]

KEYWORDS: New Jersey United States North America Canada

INDUSTRY KEYWORDS: Health Technology Other Health Fitness & Nutrition Software General Health Pharmaceutical

MEDIA:

Logo
Logo
Posted on

REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals

REMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (“MyMD”) and Akers Biosciences, Inc. (“Akers”) (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. ET to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications.

To participate in the briefing session, please click on the link below to register.

About Akers Biosciences Inc.

Akers Biosciences is pursuing rapid development and manufacturing of a COVID-19 vaccine candidate in collaboration with Premas Biotech PVT Ltd.

About MyMD Pharmaceuticals, Inc:

MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with TNF-α blocking drugs, and aging and longevity. SUPERA-1R is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. SUPERA-1R is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Important Additional Information Will be Filed with the SEC

In connection with the proposed transaction between Akers and MyMD, Akers intends to file relevant materials with the SEC, including a registration statement that will contain a proxy statement and prospectus. AKERS URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AKERS, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Akers with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Akers with the SEC by contacting Investor Relations by mail at Akers Biosciences, Inc., Attn: Investor Relations, 201 Grove Road, West Deptford, NJ 08086. Investors and stockholders are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation

Akers and MyMD, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Akers’ directors and executive officers is included in Akers’ Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 25, 2020, as amended on October 21, 2020, and the proxy statement for Akers’ 2020 annual meeting of stockholders, filed with the SEC on July 29, 2020. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement relating to the transaction when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Akers and MyMD undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction of closing conditions; the cash balances of the combined company following the closing of the merger; the ability of Akers to remain listed on the Nasdaq Capital Market in connection with the merger; and expected merger-related cash outlays, including the timing and amount of those outlays. Risks and uncertainties related to MyMD that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates, the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates, the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy.

New factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as other risks associated with the combination, will be more fully discussed in the proxy statement/prospectus that will be included in the registration statement that will be filed with the SEC in connection with the proposed transaction. Additional risks and uncertainties are identified and discussed in the “Risk Factors” section of Akers’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Akers and MyMD as of the date of this release. Neither Akers nor MyMD undertakes any obligation to update such forward- looking statements to reflect events or circumstances after the date of this release.

Investor Relations:

Hayden IR

Brett Mass, Managing Partner

Phone: (646) 536-7331

Email: [email protected]

www.haydenir.com

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Clinical Trials Biotechnology Managed Care Health Pharmaceutical General Health Other Science Science Oncology

MEDIA:

Posted on

Amwell to Participate in the 32nd Annual Piper Sandler Healthcare Conference

Amwell to Participate in the 32nd Annual Piper Sandler Healthcare Conference

BOSTON–(BUSINESS WIRE)–Amwell®, (NYSE: AMWL) (the “Company”) a national telehealth leader, today announced that Ido Schoenberg, Chairman and Co-Chief Executive Officer and Keith Anderson, Chief Financial Officer, will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference being held December 1-3, 2020. They are scheduled to participate in a fireside chat on December 3, 2020 at 1:00 p.m. EDT.

A live audio webcast and replay of this presentation will be available in the investors section of Amwell’s website at https://investors.amwell.com and will remain archived there for approximately 90 days.

About Amwell

Amwell is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 2,000 hospitals and 55 health plan partners with over 36,000 employers, covering over 80 million lives. For more information please visit https://business.amwell.com/.

American Well, Amwell, and Amwell Medical Group are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.

Media:

Holly Spring

[email protected]

781.888.8219

Investors:

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Technology Hospitals Other Technology Telecommunications Practice Management Other Health Health General Health Data Management

MEDIA:

Posted on

Celanese Launches POM ECO-B as Mass-Balance Bio-Based Option for Existing Products

Celanese Launches POM ECO-B as Mass-Balance Bio-Based Option for Existing Products

Growing specialty materials portfolio addresses sustainable POM product options

DALLAS–(BUSINESS WIRE)–
Demand for materials with renewable content and lower environmental impact is growing across customer segments. Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today launched a sustainable polyacetal (POM) product offering known as POM ECO-B to support the growing demand.

POM ECO-B allows customers to realize reduction in carbon dioxide emission in their end-use products and advance toward their renewable content goals. Celanese believes that this offering has a strong value proposition for customers in the automotive, consumer products and medical device industries where footprint reduction or renewable content is important.

Celanese’s POM ECO-B contains up to 97% bio-content via a mass-balance approach as certified by the International Sustainability and Carbon Certification (ISCC+). It reduces carbon dioxide footprint per kilogram of POM polymer by more than half without any impact on properties or need for requalification.

“Celanese is committed to enhancing our specialty materials product offerings and capabilities through ongoing investments in sustainable product developments. Today’s launch of Celanese POM ECO-B is yet another example of our focus on developing functionalized grades that meet rigorous technical specifications while offering eco-friendly content options for customers,” said Tom Kelly, Senior Vice President, Engineered Materials, Celanese.

Product Availability & Contacts

To further discuss POM ECO-B, please reach out to a Celanese commercial representative via the following regional email contacts:

For more information on product features and benefits, please visit the following website: https://www.celanese.com/engineered-materials/products/Hostaform-POM–Celcon-POM/hostaform-pom-eco-b.

For additional information regarding Celanese’s sustainability efforts and products, visit https://www.celanese.com/sustainability/.

About Celanese

Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese’s global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2019 net sales of $6.3 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

Forward-Looking Statements: This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company or its customers will realize these benefits or that these expectations will prove correct. There are a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from the forward-looking statements contained in this release. Risk factors include those that are discussed in the Company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Investor Relations

Brandon Ayache

+1 972 443 8509

[email protected]

Media Relations – Global

W. Travis Jacobsen

+1 972 443 3750

[email protected]

Media Relations Europe (Germany)

Petra Czugler

+49 69 45009 1206

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Alternative Energy Manufacturing Energy Environment Chemicals/Plastics

MEDIA:

Logo
Logo
Posted on

Verizon to redeem debt securities on December 18, 2020

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Verizon Communications Inc. (“Verizon”) (NYSE, NASDAQ: VZ) today announced that it will redeem the following notes on December 18, 2020 (the “Redemption Date”):

I.D.
Number 		Title of Security Principal Amount

Outstanding
CUSIP: 92343V CC6
ISIN: US92343VCC63
Common Code: 104629598		 3.45% Notes due 2021 (the “Notes”) $565,749,000

The redemption price for the Notes will be equal to the greater of (i) 100% of the principal amount of the Notes being redeemed or (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes being redeemed (exclusive of interest accrued to the Redemption Date) discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the Notes) plus 20 basis points (the “Redemption Price”), plus, in either case, accrued and unpaid interest on the principal amount being redeemed to but excluding the Redemption Date. The Redemption Price will be calculated in accordance with the terms of the Notes on the third Business Day (as defined in the Notes) preceding the Redemption Date.

Questions relating to the notice of redemption and related materials should be directed to the paying agent: U.S. Bank National Association, Attn: Corporate Trust Services, 111 Fillmore Ave E, St. Paul, MN 55107, or via telephone at 1-800-934-6802.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is celebrating its 20th year as one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $131.9 billion in 2019. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control.

Cautionary Statement Regarding Forward-Looking Statements

In this communication we have made forward-looking statements. These forward-looking statements are not historical facts, but only predictions and generally can be identified by use of statements that include phrases such as “will,” “may,” “should,” “continue,” “anticipate,” “believe,” “expect,” “plan,” “appear,” “project,” “estimate,” “intend,” or other words or phrases of similar import. Similarly, statements that describe our objectives, plans or goals also are forward-looking statements. These forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those currently anticipated. Factors that could materially affect these forward-looking statements can be found in our periodic reports filed with the SEC. Eligible holders are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to update publicly these forward-looking statements to reflect new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might or might not occur. We cannot assure you that projected results or events will be achieved.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at www.verizon.com/about/news/. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Media contact:

Eric Wilkens
[email protected]
201.572.9317
@ericwilkens